Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Study Demonstrates Switching from AbbVie’s Humira® (adalimumab) to Samsung Bioepis’ Biosimilar, Adalloce®, is Safe and Efficacious in NIU

Jan 9, 2024

A study published in Ocular Immunology and Inflammation found that switching patients with non-infectious uveitis (NIU) from AbbVie’s Humira® to Samsung Bioepis’ Adalloce® (SB5) did not result in clinically significant efficacy or safety differences.  The study was funded by the National Research Foundation of Korea.

On 19 December 2023, a Samsung Bioepis study published in BMJ Open Ophthalmology demonstrated SB15 was comparable to Regeneron’s Eylea® (aflibercept).